(Reuters) - Pfizer Inc reported better-than-expected quarterly profit and revenue, helped by strong demand for its pneumonia vaccine Prevnar 13 and sales of its breast cancer drug, Ibrance. The company, which also raised its full-year adjusted earnings forecast, said revenue from its global vaccines unit rose 44 percent to $1.58 billion.